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Abstract: Isoflavones are phenolic compounds with a chemical structure similar to that of estradiol.
They are present in several vegetables, mainly in legumes such as soy, white and red clover, alfalfa and
beans. The most significant food source of isoflavones in humans is soy-derived products. Isoflavones
could be used as an alternative therapy for pathologies dependent on hormonal disorders such as
breast and prostate cancer, cardiovascular diseases, as well as to minimize menopausal symptoms.
According to the results gathered in the present review, it can be stated that there is scientific evidence
showing the beneficial effect of isoflavones on bone health and thus in the prevention and treatment
of osteoporosis on postmenopausal women, although the results do not seem entirely conclusive as
there are discrepancies among the studies, probably related to their experimental designs. For this
reason, the results should be interpreted with caution, and more randomized clinical trials are
required. By contrast, it seems that soy isoflavones do not lead to a meaningful protective effect on
cardiovascular risk. Regarding cancer, scientific evidence suggests that isoflavones could be useful in
reducing the risk of suffering some types of cancer, such as breast and endometrial cancer, but further
studies are needed to confirm these results. Finally, isoflavones could be useful in reducing hot
flushes associated with menopause. However, a limitation in this field is that there is still a great
heterogeneity among studies. Lastly, with regard to isoflavone consumption safety, it seems that they
are safe and that the most common adverse effect is mild and occurs at the gastrointestinal level.
Keywords: isoflavones; flavonoids; phytoestrogens; soy; bone health; cardiovascular risk; cancer;
menopausal symptoms
1. Introduction
Phenolic compounds are secondary metabolites, which are produced by plants as a defense
mechanism against infection, water stress, cold stress, ultraviolet radiation and high visible light,
among others [1,2]. Phenolic compounds, characterized by the presence of a hydroxyl group attached
to at least one aromatic ring, can be classified as flavonoids and non-flavonoids. Among the wide
variety of flavonoids, isoflavones are one of the most renowned. Due to its structural similarity to the
estrogen-like compound 17β-estradiol (Figure 1), they are referred to as phytoestrogens. Consequently,
isoflavones can have estrogenic or anti-estrogenic effects [3].
Nutrients 2020, 12, 3853; doi:10.3390/nu12123853 www.mdpi.com/journal/nutrients
Nutrients 2020, 12, 3853 2 of 25
Nutrients 2020, 12, x FOR PEER REVIEW 2 of 25 
 
 
Figure 1. Chemical structure of 17β-estradiol. Modified from Wang et al., 2006 [4]. 
Isoflavones have received attention due to their putative healthy properties. In this sense, it has 
been described that both isoflavones and other estrogenic molecules could mediate their beneficial 
effects due to two different mechanisms: the classical estrogen receptor (ER)-mediated signaling 
pathway and the activation of intracellular pathways such as protein tyrosine kinase, phospholipase 
C and mitogen-activated protein kinase (MAPK) [5,6]. In the aforementioned mechanism, it has been 
reported that isoflavones bind to both ERα and ERβ, although they present a higher affinity towards 
ERβ receptors [7]. Moreover, even though the binding affinity of isoflavones to the ER receptors is 
less than that of 17β-estradiol, they can also act as estrogenic compounds when the endogenous 
estradiol is not available [8]. Thus, its consumption, according to epidemiological and clinical studies, 
has been postulated to be related to a decrease in the risk of different diseases. The aim of the present 
review is to gather the scientific evidence existing nowadays on the main beneficial effects of 
isoflavones on health: bone health, cardiovascular risk, cancer and menopausal symptoms. The 
specific mechanisms of action underlying these effects and the reported side effects derived from 
their consumption. 
2. Oral Intake and Occurrence 
Isoflavones are found in several vegetables, mainly in legumes (Fabaceae family) such as soy, 
white and red clover, alfalfa and beans [9,10]. The most significant food source of isoflavones in 
humans is soy-derived products, soybeans, soy flour, soy flakes, soy beverages and fermented soy 
products such as miso and tempeh, among others [9]. Although smaller in quantity, isoflavones are 
also present in chickpeas, nuts, fruits and vegetables [11]. 
The main isoflavones found in foodstuffs are daidzein, genistein and glycitein, as well as 
biochanin A and formononetin [9,12]. Some authors label equol as an isoflavone; however, since it is 
a daidzein-derived bacterial metabolite and not a naturally occurring isoflavone, this classification is 
not correct [10]. Nevertheless, it is important to consider this metabolite since it is key in the biological 
activity of isoflavones [13]. As with other phenolic compounds, isoflavones can be presented as free 
forms (aglycones) or conjugated with carbohydrates (glycosides). The latter is the most common form 
in foodstuffs, with the exception of fermented soy products, such as miso and tempeh. In miso and 
tempeh, the aglycone form is the most abundant one [9]. In soybeans, the three most abundant 
isoflavones are present in four chemical forms: aglycone, glycoside, acetylglycoside and 
malonylglucoside (Table 1 and Figure 2). The aglycone and conjugate forms of genistein represent 
up to 60% of total isoflavones, this being up to 30% in the case of daidzein. The main forms of 
conjugates in soybeans are the malonyl derivatives [14]. 
Table 1. Presence of four chemical forms of the three isoflavones found in soybeans. 
Isoflavone Content and Chemical Forms in Soybeans 
Aglycones Daidzein, genistein, glycitein 
Glycosides Daidzin, genistin, glycitin 
Acetylglycosides Acetyldaidzin, acetylgenistin, acetylglycitin 
Malonylglycosides Malonyldaidzin, malonylgenistin, malonylglycitin 
Figure 1. Chemical structure of 17β-estradiol. odified from Wang et al., 20 6 [4].
Isoflavones have received attention due to their putative healthy properties. In this sense, it has
been described that both isoflavones and other estrogenic molecules could mediate their beneficial
effects due to two different mechanisms: the classical estrogen receptor (ER)-mediated signaling
pathway and the activation of intracellular pathways such as protein tyrosine kinase, phospholipase C
and mitogen-activated protein kinase (MAPK) [5,6]. In the aforementioned mechanism, it has been
reported that isoflavones bind to both ERα and ERβ, although they present a higher affinity towards
ERβ receptors [7]. Moreover, even though the binding affinity of isoflavones to the ER receptors is less
than that of 17β-estradiol, they can also act as estrogenic compounds when the endogenous estradiol
is not available [8]. Thus, its consumption, according to epidemiological and clinical studies, has been
postulated to be related to a decrease in the risk of different diseases. The aim of the present review is
to gather the scientific evidence existing nowadays on the main beneficial effects of isoflavones on
health: bone health, cardiovascular risk, cancer and menopausal sympto s. The specific echanisms
of action underlying these effects and the reported side effects derived from their consumption.
2. Oral Intake and Occurrence
Isoflavon s are found i several vegetables, mainly in legumes (Fabaceae family) such as soy,
white and red clover, alfalfa and beans [9,10]. The most significant food source of isoflavones in
humans is soy-derived products, soybeans, soy flour, soy flakes, soy beverages and fermented soy
products such as miso and tempeh, among others [9]. Although smaller in quantity, isoflavones are
also present in chickpeas, nuts, fruits and vegetables [11].
The main isoflavones found in foodstuffs are daidzein, genistein and glycitein, as well as
biochanin A and formononetin [9,12]. Some authors label equol as an isoflavone; however, since it is
a daidzein-derived bacterial metabolite and not a naturally occurring isoflavone, this classification
is not correct [10]. Nevertheless, it is important to consider this metabolite since it is key in the
biological activity of isoflavones [13]. As with other phenolic compounds, isoflavones can be presented
as free forms (aglycones) or conjugated with carbohydrates (glycosides). The latter is the most
common form in foodstuffs, with the exception of fermented soy products, such as miso and tempeh.
In miso and tempeh, the aglycone form is the most abundant one [9]. In soybeans, the three most
abundant isoflavones are present in four chemical forms: aglycone, glycoside, acetylglycoside and
malonylglucoside (Table 1 and Figure 2). The aglycone and conjugate forms of genistein represent up
to 60% of total isoflavones, this being up to 30% in the case of daidzein. The main forms of conjugates
in soybeans are the malonyl derivatives [14].
Table 1. Presence of four chemical forms of the three isoflavones found in soybeans.
Isoflavone Content and Chemical Forms in Soybeans
Aglycones Daidzein, genistein, glycitein
Glycosides Daidzin, genistin, glycitin
Acetylglycosides Acetyldaidzin, acetylgenistin, acetylglycitin
Malonylglycosides Malonyldaidzin, malonylgenistin, malonylglycitin
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Figure 2. The four chemical forms of the three most abundant isoflavones. 
With regard to isoflavone content in foodstuffs, it has been observed that in soybeans, the 
amount of these phenolic compounds ranges from 1.2 to 4.2 mg per g on dry weight, whereas in red 
clover, the amount varies between 10 and 25 mg per g on dry weight [15,16]. Even though red clover 
has a greater amount of isoflavones, it is not an edible plant, and it is consumed as a food complement. 
Thus, soybean can be considered as the best food source. Isoflavone content in soy-derived products 
is usually lower than in soybeans [17]. Importantly, the soy variety, environmental conditions of the 
culture and the processing of soybeans notably influence their isoflavone content [18]. Furthermore, 
isoflavones are associated with proteins; thus, alcohol extraction and processing diminish isoflavone 
content in foodstuffs such as fermented soybean, tofu or soy beverages. By contrast, the total 
isoflavone amount is high in soy flour, protein isolate or edamame [19]. 
Focusing on the overall intake of isoflavones in humans, several studies have reported varied 
results. In general terms, it has been observed that in Asian countries where there is high 
consumption of soy and its derived foodstuffs, isoflavone intake is high, ranging from 15 to 60 
mg/day [20,21], whereas, in western countries, it is notably lower, around 1–2 mg/day [22–24]. 
3. Bioavailability 
As previously mentioned, soybeans and their derived foodstuffs are the main isoflavone sources 
in the human diet, at least if we do not consider red clover extract supplements, which are being 
widely used by menopausal women as “nutraceutical therapy” [13]. For this reason, the 
bioavailability of isoflavones has been extensively characterized in animal models and humans [25–
27]. 
Isoflavone glycosides have to be hydrolyzed to the aglycone form prior to its absorption by 
passive diffusion in the upper small intestine [28]. The enzymes responsible for the hydrolysis of 
isoflavone glycosides are glucosidases, which can be produced by the intestinal mucosa or the 
microbiota [29]. The enzyme lactase-phlorizin hydrolase (LPH) deglycosylases phenolic compounds 
in the intestinal lumen, and after that, the aglycone form enters the epithelial cells by passive 
diffusion. Moreover, sodium-dependent glucose transporter 1 (SGLT1) allows phenolic compound-
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With regard to isoflavone conte t i foodstuff , it has been o s rved that in soybeans, the amount
of these phenolic compounds ranges from 1.2 to 4.2 mg per g on dry weight, hereas in red clover,
the amount varies betw en 10 and 25 mg per g on dry weight [15,16]. Even thoug red clover has
a gre ter mount of is flavones, it is not an edible plant, and it s consumed as a fo d comple ent.
Thus, soybean can be considered as the best fo d source. Isoflavone content in soy-derived products
is usually lower than in soybeans [17]. I portantly, the soy variety, environmental conditions of the
culture and the proces ing of soybeans notably influence their isoflavone content [18]. Further ore,
isoflavones are as ociated with proteins; thus, alcohol extraction and proces ing diminish isoflavone
content in foodstuffs such as fermented soybean, tofu or soy beverages. By contrast, the tot l isoflavone
amount is high in soy flour, protein isolate r edamame [19].
Focusing on the overall intake of isoflavones in humans, several studies have reported varied
results. In gen ral terms, it has been o s rved that in Asi n countries where there is high consumption
of soy and its derived foodstuffs, isoflav ne intake is high, ranging from 15 to 60 mg/day [20,21],
where s, in western countries, it is notably lower, around 1–2 mg/day [22–24].
3. Bioavailability
As previously mentioned, soybeans and their derived foodstuffs are the main isoflavone sources
in the human diet, at least if we do not consider red clover extract supplements, which are being widely
use b menopausal women as “nutraceutical therapy” [13]. For this reason, the bioavailability of
isofla ones has been extensively characterized in animal models and hu ans [25–27].
Isoflavone glycosides have to be hydrolyzed to the aglycone form prior to its absorption by
passive diffusion in the upper small intestine [28]. T e enz mes responsible for the hydrolysis
of isoflavone glycosides are glucosidases, which can be produced by the intestinal mucosa or the
microbi ta [29]. The enzyme lactase-phlorizin hydrolase (LPH) deglycosylases phenolic compounds
in the intestinal lumen, and after that, the aglycone form enters the epithelial cells by passive diffusion.
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Moreover, sodium-dependent glucose transporter 1 (SGLT1) allows phenolic compound-glycosylates
to directly enter into epithelial cells, where they are hydrolyzed by cytosolic glucosidases [30,31].
Interestingly, in a study conducted by Tamura et al., the authors observed that in individuals without
the LPH enzyme, the concentration of isoflavones and derived metabolites was similar to that found
in individuals without an enzyme deficiency. This finding suggests that bacterial deglycosylation
contributes significantly to isoflavone absorption [32]. Daidzein, genistein and glycitein occur naturally
in the aglycone form, and thus their absorption is faster than that of others.
It has been described that after the oral intake of isoflavones, their peak plasma concentration in
humans occurs at around seven hours [33]. As in the case of other phenolic compounds, genistein and
daidzein undergo phase II xenobiotic metabolism, mainly glucuronidation and sulfation reactions at
4’and/or 7’ positions of the isoflavone ring [34,35]. Produced metabolites appear in plasma at variable
concentrations and can enter enterohepatic circulation [28]. In a study reported by Ko et al., the authors
quantified the plasma concentrations of daidzein, genistein, glycitein and equol in Korean men and
women [36]. After the consumption of around 17 mg of isoflavones per day, the median plasma
concentrations of genistein, glycitein, daidzein and equol were 245.3 ng/mL, 9.8 ng/mL, 86.8 ng/mL
and 12.7 ng/mL, respectively.
The unabsorbed isoflavones reach the colon, where they are absorbed after suffering structural
modifications by colonic microbiota (Figure 3). Daidzein is first converted into dihydrodaidzein,
which is the precursor of both equol and O-demethylangolensin (O-DMA) [37]. Equol has been
considered as the most interesting colonic metabolite due to its beneficial biological activity,
which differs from that of its precursor, daidzein [13,38,39]. In addition, genistein and glycitein are
transformed into dihydrogenistein and dihydroglycitein, respectively, before being further converted
into other metabolites. Nevertheless, the metabolism of formononetin and biochanin A, the main
isoflavones in red clover, has been less studied due to their limited presence in foodstuffs. Anywise,
it has been observed that both isoflavones are demethylated by microbiota, formononetin to daidzein
and biochanin A to genistein. After this, each metabolite undergoes its own metabolic pathway [40].
In addition, it is important to highlight that interindividual differences in gut bacterial populations
are responsible for the diverse effects of isoflavones in humans. While equol production seems to be
similar in animals, it is very variable in humans [41], and therefore, beneficial effects referred to equol
have been observed only in individuals with a specific microbiota composition [38].
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Isoflavone excretion occurs mainly through urine and feces, primarily in the conjugate forms, and
up to 95% takes place in 24 h [43]. In addition, several studies have observed that the urine excretion of
daidzein metabolites is notably higher than that of genistein metabolites [44–46]. In a study conducted
by Karr et al., the authors analyzed the urinary excretion of genistein, daidzein, equol and O-DMA in
fourteen young men and women [47]. They observed that it was dose-dependent at low to moderate
soybean consumption.
4. Biological Activity
Isoflavones could be used as an alternative therapy for pathologies dependent on hormonal
disorders such as breast and prostate cancer, cardiovascular diseases, as well as to minimize menopausal
symptoms. For the development of this section, the meta-analyses and systematic reviews published
between 2015 and 2020 were taken into account.
4.1. Bone Health Maintenance
During menopause, there is a loss of bone density that can cause osteoporosis. In this sense, soy
isoflavones have been proposed as beneficial because, in theory, they may contribute to the maintenance
of good bone health (mass, mineral density and bone structure) in women who are at this stage in their
life. Regarding this topic, three systematic reviews and three meta-analyses were analyzed (Table 2).




















































































































In the systematic review reported by Perna et al. (2016), nine studies addressed to menopausal
women and focused on bone health were analyzed [52]. The authors indicated that no consensus
was found regarding the protective effects of soy isoflavones (20–80 mg) and equol (10 mg) on bone
resorption. Abdi et al. (2016) published another systematic review of 23 randomized controlled trials to
determine the effect of soy isoflavone extracts on bone mineral density in postmenopausal women [51].
The conclusion was that isoflavones exerted little influence over bone mineral density and thus over
bone health during menopause, although not all the studies observed the same effect. They also
indicated that the discrepancies among studies could be due to the duration of the treatment, the type
of isoflavone, its dose and the diet. Regarding the effect of specific isoflavones, they suggested that
genistein, alone or in combination with daidzein, improved bone density and bone turnover in women
after menopause. However, the authors stated that they could not reach definitive conclusions due
to, among other reasons, the lack of inclusion in the review of randomized controlled clinical trials
focused on the treatment of osteoporosis in early menopause. In a more recent systematic review,
including two meta-analyses, as well as one multicenter and randomized controlled trial, Chen and his
team concluded that isoflavones reduced lumbar spine bone mineral density loss [53]. It is important
to point out that the spine has a high proportion of trabecular bone and that this is probably the reason
why the spine is thought to be more sensitive to isoflavones.
With regard to the published meta-analysis, the studies included were restricted to randomized
controlled trials. The work reported by Lambert et al. (2017) included 26 trials with 2652 participants [48].
It supports the evidence that isoflavones can moderately attenuate bone resorption in women with low
estrogen levels, primarily at the level of the lumbar spine and the femoral neck. They also note that
the effects of isoflavones are greater when administered as aglycones. This fact was not taken into
account in previous meta-analyses, and thus it may justify the discrepancies amongst them. In this
line, another meta-analysis, which included 52 controlled trials and 5313 patients, shows that soy
isoflavones have beneficial effects on bone mineral density in the femur neck, lumbar spine, and hip,
regardless of body weight or ethnicity [49]. The improvement was greater in treatments lasting more
than one year and in subjects with normal weight, probably because subjects with excessive body
weight have a lesser risk of bone loss. In contrast, the effects on bone resorption biomarkers were more
favorable in overweight or obese women than in women with a healthy weight. Sansai et al. (2020)
carried out their meta-analysis of 63 controlled trials, including 6427 postmenopausal women and
concluded that isoflavones improve bone density at the lumbar spine, femoral neck and the distal
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radius in menopausal women [50]. These positive effects were associated with 54 mg/day of genistein
and 600 mg/day of synthetic isoflavone ipriflavone.
In view of these results, we can conclude that there is scientific evidence that supports the
beneficial effect of isoflavones on bone health and thus in the prevention and treatment of osteoporosis
in postmenopausal women. However, the results do not seem entirely conclusive, for there are
discrepancies among the studies, probably related to their experimental designs. For this reason,
the results should be interpreted with caution, and more randomized clinical trials are required.
Although the mechanisms of action of isoflavones are not completely understood, it seems that
isoflavones not only reduce the rate of bone resorption but also increase the rate of bone formation.
The enhanced bone formation is due to the stimulation of osteoblastic activity mainly through (a) the
activation of estrogen receptors because they bind to nuclear estrogen receptors and exhibit estrogenic
activity due to its similarity to 17β-estradiol, and (b) the promotion of insulin-like growth factor-I
(IGF-I) production [54,55] (Figure 4).
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4.2. Cardiovascular Risk
In some Asian countries, isoflavone intake, usually derived from soy consumption, can be
associated ith a lower prevalence of cardiovascular diseases (CVDs). In this revision, three systematic
reviews and five meta-analyses were included to explore the association of isoflavones and markers
related to CVDs (Table 3).
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Table 3. Effects of isoflavones in cardiovascular disease-related markers.
Authors Number ofStudies Included Type of Studies Included
Number of Participants and
Gender/Age/Characteristics Compound and Doses Observed Effects
Meta-analysis
Kim and Je, 2017 [56] 13 Prospective studies
338,541 participants
Age ranging from 40–84 years
Follow-up period from 4 to 28 years
Intake data not provided No association with mortalityfrom CVD
Yan et al., 2017 [57] 17 Prospective cohort andcase-control studies
508,841 participants, 17,269 with
CVD events (stroke, coronary heart
disease, ischemic stroke)
Follow-up period from 6.3 to 16 years
Isoflavones 0.025–53.6 mg/day
No associations between soy
isoflavones consumption and risk
of cardiovascular disease, stroke,
and coronary heart disease
Abshirini et al., 2020 [58] 5 Randomized clinical trials
548 participants















(276 women and 209 men)
Age ranging from 35–75 years
Isoflavones 80–118 mg/day
and 10 mg/day of S-equol
Intervention period:
1 day–12 weeks
Positive effect of soy isoflavones
on arterial stiffness
Systematic reviews
Perna et al., 2016 [52] 12 Randomized clinical trials 139–1268 menopausal andpostmenopausal women
Isoflavones 20 to 100 mg/day
Intervention period:
8 weeks–2 years
Reduction in total cholesterol and
triglyceride plasma
concentrations








337 healthy, diabetic or
hypercholesterolemic individuals
Age: 18–74 years
406 healthy, postmenopausal or
obese participants
Age: 50–79 years
Isoflavones 3 to 102 mg/day
Intervention period:
4–208 weeks
Isoflavones 60 to 135 mg/day
Intervention period:
3–12 months
Reduction in total cholesterol and
LDL cholesterol
Changes in systolic or diastolic
blood pressure (increase and
decrease, depending on
the study)
Rienks et al., 2017 [61] 3 Prospective studies 68,748 individualsAge: 40–70 years
Follow-up period: up to
10 years





CVD: cardiovascular disease, LDL: low-density lipoprotein.
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In their systematic revision, which included 1307 menopausal (n = 139) and post-menopausal
(n = 1268) women, Perna et al. (2016) suggested that a daily intake of soy isoflavones, ranging from
20 to 100 mg/day, reduced total cholesterol and triglyceride plasma concentrations, as well as some
markers of oxidative stress (nitric oxide and malonaldehyde), thus reducing cardiovascular risk [52].
Further, Chalvon-Demersay et al. aimed to compare the effects of animal and plant-sourced proteins
on lipemia and blood pressure [60]. In this systematic review, 123 studies were included, with a
total number of 516,330 participants. The authors found, in a small number of studies (17 studies
including 337 healthy, diabetic or hypercholesterolemic individuals), that a soy protein-based diet
(rich in isoflavones) as compared to animal protein-based diets (meat, milk, casein, whey) resulted in
reduced total cholesterol or LDL-cholesterol concentrations, increased HDL cholesterol concentrations,
improved LDL:HDL cholesterol ratio, and decreased triglycerides. Interestingly, soy protein isolate
(void of isoflavones through alcoholic extraction during the protein solation phase) did not show these
effects. Regarding blood pressure, inconsistent results were reported in three further interventional
studies (n = 406 healthy, postmenopausal or obese participants aged 50–79 years) either in diastolic or
systolic blood pressure, after a supplementation with soy-protein.
In another systematic review of three observational studies (including 68,748 participants),
low evidence of isoflavones was shown in the prevention of cardiovascular diseases [61]. The authors
concluded that evidence for the role of isoflavones and soy products in the prevention of cardiovascular
diseases was scarce and inconclusive.
Two meta-analyses, which covered prospective cohort studies, showed that soy isoflavone
consumption was not associated significantly with mortality linked to cardiovascular events [56,62].
Indeed, Kim and Je (2017) indicated that a high intake of flavonoids is associated with a reduced risk of
mortality from cardiovascular diseases in men and women [56]. However, when a subgroup analysis
by a class of flavonoids was carried out, they concluded that these inverse associations were significant
for all categories of flavonoids except for isoflavones and flavonols.
Additionally, Yan and co-workers, in their meta-analysis with a total of ten prospective cohorts and
seven case-control studies (including 508,841 participants and 17,269 cardiovascular disease events),
observed that the consumption of soy foods, but not that of isoflavones, was associated with a lower
risk of total cardiovascular disease (including coronary heart disease and stroke) [57]. This fact suggests
that other components, such as fiber in the soy foods, may account for these negative associations.
In like manner, a meta-analysis by Simental-Mendía et al. (2018) showed no effect of soy isoflavones
on plasma concentrations of lipoprotein a (Lpa), a low-density lipoprotein associated with increased
cardiovascular risk due to its pro-thrombotic and atherogenic properties [63].
Lastly, Abshirini et al. (2020) revised the literature to find randomized controlled trials
that evaluated the impact of soy protein supplementation (isoflavone intake ranging from 49.3 to
118 mg/day) on endothelial function parameters in postmenopausal women (n = 802) [58]. Apparently,
soy isoflavones modified adhesion molecules by binding to vascular endothelium and mimicking
the effect of a modulator of estrogen receptors [64]. Furthermore, soy protein has been linked to an
improvement in nitric oxide production and contributes to increased arterial compliance [65]. However,
in the meta-analysis, a minor enhancement in flow-mediated dilation after soy protein supplementation
was found. On the contrary, a systematic review and meta-analysis reported by Man et al. (2020)
revealed that supplementation of soy isoflavones had a positive effect in reducing arterial stiffness,
also known as the loss of arterial elasticity [59]. The physical stiffening of arteries has major health
implications for its connection to various adverse cardiovascular and other health outcomes such as
coronary heart disease, stroke, hypertension or heart failure [66]. However, the authors acknowledged
several limitations to their study, such as the small sample size in the meta-analysis (middle-aged
276 women and 209 men), and recognized that a large number of subjects as well as a lengthier
intervention are needed to investigate whether supplementation of soy isoflavones actually improves
these outcomes.
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Taken as a whole, all these results suggest that soy isoflavones do not lead to a meaningful
protective effect on cardiovascular risk. It follows that additional high-quality, large-scale randomized
controlled trials are needed.
As far as the mechanisms of action involved in the decrease in triglyceride concentration are
concerned, it has been reported that hepatic lipase and/or lipoprotein lipase activity may be increased
as a result of isoflavone presence. Indeed, some authors speculate that hepatic and lipoprotein lipase
activity may have been altered after variable isoflavone intake from soybean, although no experimental
data were provided [67]. Since hepatic lipase and lipoprotein lipase hydrolyze triglycerides into their
constituents glycerol and fatty acids, their activation results in the delivery of the fatty acids to tissues
such as muscle and adipose tissue.
4.3. Cancer
Some epidemiological studies indicate that the incidence of some types of cancer is lower in
eastern countries than in western ones. This fact does not seem to be influenced by genetics since
migrating from eastern to western countries appears to cause the loss of this protective effect. In this
section, 16 meta-analyses have been revised: Nachvack et al. (2019) conducted a meta-analysis where
23 prospective studies with a total of 330,826 participants were included. The authors observed that
soy isoflavone consumption was inversely associated with cancer deaths. Moreover, a higher intake of
soy isoflavones was associated with a lower risk of mortality from gastric, colorectal, and lung cancers.
Indeed, they reported that an increase of 10 mg/day of soy isoflavones consumption was associated
with a 7% lower risk of cancer mortality [62].
Regarding breast cancer (Table 4), the same increase in soy isoflavone intake (10 mg/day) was
related to a 9% lower risk of breast cancer mortality. However, it is important to point out that
the beneficial effects of soy isoflavone consumption have been exhibited by women with estrogen
receptor-negative breast cancer, but not by women with receptor-positive breast cancer, who present
a better prognosis [62]. In this sense, Micek et al. (2020) carried out a meta-analysis with 15 cohort
studies with the aim of exploring the association between isoflavone intake (<62.7 mg/day) and breast
cancer mortality and its recurrence [68]. The authors found a significant inverse association between
isoflavone intake and both overall mortality and breast cancer recurrence. These two associations were
significant for postmenopausal participants. In addition, Qiu et al. (2018) analyzed 12 studies with
37,275 women with breast cancer and reported that soy isoflavone consumption at a pre-diagnosis
stage might have a small effect on the survival of postmenopausal women with breast cancer [69].
However, the authors pointed out several limitations of this study, such as the important source of
heterogeneity in their study. In fact, the number of isoflavones present was very variable among the
different soy food types. Therefore, it is necessary to support these results with additional studies.
Future research in this field should quantify isoflavones as accurately as possible, analyzing larger
cohorts and lengthening the follow-up stage. Moreover, the number of publications grouping women
according to pre- or post-diagnosis intake criteria is small.
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Nachvack et al., 2019
[62] 23 Prospective study
330,826
(12 studies in both genders
and 11 in women)
Soy/soy products
(10 mg/day)
Inverse association with cancer deaths.
7% lower risk of gastric, colorectal, and lung
cancer mortality
Breast cancer
Nachvack et al., 2019
[62] 23 Prospective study
330,826
(12 studies in both genders
and 11 in women)
Soy/soy products
(10 mg/day)
9% lower risk of estrogen receptor-negative breast
cancer mortality
Micek et al., 2020 [68] 15 Cohort study 49,659 Isoflavone intake (0.0036–62.7 mg/day) Inverse association between isoflavone intake andboth overall mortality and breast cancer recurrence
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High dietary intake of soy foods (dose
non-defined) Significant reduction of breast cancer risk
Rienks et al., 2017 [61] 10 Case-control study Sample sizes (from 100 to15,688 participants)
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Soy products (0.05–130 g/day) and total
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19% reduction in endometrial cancer risk.
Higher reduction in Asian women
Liu et al., 2016 [72] 23 Randomizedcontrolled trials 2167 More than 54 mg isoflavone/day
Reduction of the endometrial thickness in North
American women (for 0.23 mm). Opposite effect in
Asian women
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Isoflavone consumption (>45 mg/day
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6275 cases and
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4.84–5.97), and equol (Japanese: 10.3–24;
European: 0.25–0.65)
Genistein, daidzein and equol did not affect prostate
cancer risk in both Japanese and European men
Applegate et al., 2018
[76] 30
Case-control study (15)
Cohort study (8) Nested
case-control study (7)
266,699 (21,612 patients with
prostate cancer) Soy foods (<90 mg/day)
Isoflavones were not associated with a reduction of
prostate cancer risk
Metabolites (genistein and daidzein) consumption
was associated with a reduction of prostate cancer risk
Rienks et al., 2017 [61] 8 Case-control study Sample sizes(10–15,688 participants)
Daidzein, genistein, and equol (dose
not defined)
19% reduction in prostate cancer risk was found at
high concentrations of daidzein, but not with
genistein or equol
Zhang et al., 2017 [77] 23 Case-control study (21)Cohort study (2)
Participants: 11,346 cases and
140,177 controls
Daidzein, genistein, and equol (dose
not defined)
Daidzein and genistein intakes were associated with a
reduction of prostate cancer risk (no effect with equol)
Colorectal cancer
He et al., 2016 [78] 18 Case-control study (9)Cohort study (9)
559,486 (among them 16,917
colorectal cancer cases)
Foods rich in isoflavones (dose
not defined)
Reduction of colorectal cancer risk.
This association is stronger among postmenopausal
women than premenopausal women




272,296 participants Soy foods (30 mg/day–170 g/day) andisoflavones (0.014–60 mg/day)
23% reduction in colorectal cancer risk.
Potential protective effect in the Asian population
(their consumption is higher than in the
Western population)
Jiang et al., 2016 [80] 17 Case-control study (9)Cohort study (8) 317,599 participants Isoflavones (0.025–74 mg/day).
Inverse association between isoflavone consumption
and colorectal cancer risk in case-control studies, but
not in cohort studies.
8% reduction in colorectal neoplasm risk for every
20 mg/day increase in isoflavone intake (Asian
population) and for every 0.1 mg/day increase
(Western population)
Gastric cancer
You et al., 2018 [81] 12 Cohort study (6)Case-control study (6) 596,553 participants
Isoflavones (high dose: 0.6–75.5 mg/day;
and low dose: 0.01–20.1 mg/day).
No association between isoflavone consumption and
gastric cancer risk with the highest versus the lowest
categories of dietary isoflavone intake
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Another meta-analysis, conducted by Zhao et al. (2019), included 16 prospective cohort studies
involving 11,169 breast cancer cases and 648,913 participants [70]. The authors studied all possible
correlations between isoflavone consumption and the risk of breast cancer. While a moderate intake of
soy isoflavones did not significantly affect breast cancer risk, a significant reduction was shown when
the intake was high. However, some limitations were found in these prospective studies, such as the
small sample size of the cohorts and the unspecific definition of high, moderate and low isoflavone
intake. Moreover, Rienks et al. (2017) conducted a meta-analysis with ten observational studies to
assess the association between the isoflavone compounds daidzein, genistein and equol, and breast
cancer [61]. The authors indicated that high concentrations of daidzein and genistein (no specific
values concerning these concentrations were available) were related to 34% and 28% reduction in
breast cancer risk, respectively, whereas no association with equol was found. In conclusion, this study
reported some evidence that suggests the beneficial role that daidzein and genistein play in preventing
breast cancer risk. Furthermore, among the four studies of breast cancer recurrence, three studies
found that isoflavone intake decreased the risk of breast cancer recurrence, although further studies
are required to confirm this finding [82].
Endometrial cancer (Table 4), as well as breast cancer, is an estrogen-dependent cancer type related
to high circulating estradiol concentrations. In this line, three meta-analyses were conducted to study
isoflavone consumption and endometrial cancer risk. Zhong et al. (2018) revised 13 epidemiologic
studies involving 178,947 participants: 7067 cases and 171,880 controls; among them, three were
prospective cohort studies, and ten were population-based case-control studies [71]. The authors
reported that isoflavone intake from soy products and legumes was associated with a 19% reduction
in endometrial cancer risk. However, the magnitude of risk reduction in Asian women was slightly
larger than in non-Asian women (22% vs. 18%). Diversely, Liu et al. (2016) analyzed the effect of oral
isoflavone supplementation on endometrial thickness in pre- and post-menopausal women, which is a
biomarker for the proliferative effects of estrogens associated with an increased endometrial risk [72].
For this purpose, 23 studies with 2167 patients were included in this meta-analysis, which showed
that a daily dose of more than 54 mg could decrease the endometrial thickness in North American
women, whereas the contrary effect was observed in the Asian sample. The authors suggested that
this difference could be due to different genetic backgrounds and dietary patterns among Asian and
Western populations. Grosso et al. (2017) carried out a meta-analysis of 143 case-control studies,
where isoflavone intake was associated with endometrial, ovarian, and breast cancers [73]. Regarding
endometrial cancer, three prospective and five case-control studies were analyzed, which suggested a
lower endometrial cancer risk associated with isoflavone consumption. However, more studies are
required to provide stronger evidence.
Hua et al. (2016) conducted a meta-analysis aimed at ovarian cancer, which affects women
exclusively [74]. In this study, five prospective cohort studies and seven case-control studies,
with 6275 cases and 393,776 controls, were included. The results indicated that the isoflavone
intake decreased the ovarian cancer risk by 33%. Therefore, the authors concluded that the intake of
dietary isoflavones paid a protective role against ovarian cancer.
With regard to prostate cancer, it has been proposed that it might be affected by isoflavone
consumption due to its effect on hormone metabolism. Four meta-analyses have been reported to
address this issue. Pérez-Cornago et al. (2018) published a meta-analysis of seven prospective cohort
studies (two studies from Japan with 241 cases and 503 controls, and five studies from Europe with
2828 cases and 5593 controls) [75]. In Japanese men, pre-diagnostic circulating levels of genistein,
daidzein and equol did not significantly affect prostate cancer risk. In the same line, in European men,
isoflavone concentrations did not affect the risk of developing prostate cancer. In the meta-analysis
reported by Applegate et al. (2018), 30 articles were included for analysis; 15 of them were case-control
studies, eight cohort studies and seven nested case-control studies [76]. This meta-analysis included
266,699 participants (21,612 patients with prostate cancer among them). The authors reported that
neither soy food intake nor circulating isoflavones were associated with a reduced risk of prostate
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cancer. However, the intake of specific isoflavones, genistein and daidzein, was indeed significantly
associated with a reduced risk of this type of cancer. The authors suggested that further studies
grouping subjects by isoflavone intake or by the circulating isoflavone levels might enhance this
association. Rienks et al. (2017) also analyzed eight studies of prostate cancer, and they found an
association between isoflavone intake and prostate cancer risk [61]. A significant 19% reduction of
the risk was found at high concentrations of daidzein, but not at genistein or equol concentrations.
Lastly, Zhang et al. (2017) conducted a meta-analysis with 21 case-control studies and two cohort
studies, with a total number of 11,346 cases and 140,177 controls [77]. They observed that daidzein and
genistein intakes were associated with a significant reduction of prostate cancer risk. Nevertheless,
this association was not shown when equol or isoflavones were consumed. Moreover, the authors
suggested that ethnicity could have had influenced this association, but studies with larger sample
sizes are needed to confirm this hypothesis.
Due to the high prevalence of colorectal cancer, three meta-analyses addressing this issue are
included in the present review. He et al. (2016) conducted a meta-analysis of 18 studies involving
16,917 colorectal cancer cases in 559,486 participants [78]. The results showed that a higher regular
intake of foods rich in isoflavones might potentially decrease colorectal cancer incidence. Moreover,
this association was more prominent among postmenopausal women than premenopausal women.
However, the authors suggested that more prospective cohort studies are needed to further investigate
this association and that the quantity of isoflavone intake should be accurately measured because
flavonoid contents in food can vary significantly. In the same line, Yu et al. (2016) published a
meta-analysis of 13 case-control and four prospective cohort studies, where the results revealed that soy
isoflavone consumption reduced the risk of developing colorectal cancer by 23% [79]. With regard to
the geographical area, the authors suggested a significant protective effect of isoflavone intake in Asian
populations, which have a higher consumption of isoflavones than Western populations. For their
meta-analysis, Jiang et al. (2016) included 17 studies (nine case-control studies and eight cohort
studies) [80]. The authors found a statistical inverse association between isoflavone consumption
and colorectal cancer risk in case-control studies, although not in cohort studies. Furthermore,
the dose-response analysis revealed an 8% reduction in colorectal neoplasm risk for every 20 mg/day
increase in isoflavone intake in Asian populations, and for every 0.1 mg/day increase in Western
populations. The difference for isoflavones required to find an effect can be due to variations in the
amount of isoflavone intake between both populations. Thus, whereas Asian populations have an
average isoflavone consumption of >30 mg/day, Western populations consume <1 mg/day [83].
Lastly, the association between dietary isoflavone intake and the risk of developing gastric cancer
has also been analyzed. You et al. (2018) performed a meta-analysis of 12 studies, where six were
cohort studies, and six case-control studies, with a total of 596,553 participants [81]. The results showed
no significant association between isoflavone consumption and gastric cancer risk, with the highest
(0.6–75.5 mg/day) versus the lowest (0.01–20.1 mg/day) categories of dietary isoflavone intake. In this
sense, the authors suggested that the composition of the gut microflora may influence isoflavone
absorption and metabolism and could affect the production of isoflavone metabolites, which, in turn,
could mediate their biological activity.
Overall, evidence regarding the use of isoflavones in cancer prevention suggests that they may
be useful in reducing the risk of suffering from some types of cancer, such as breast and endometrial
cancer, two of the types for which the association between isoflavone intake and cancer risk has been
studied more in-depth. However, all the authors agree that further studies are necessary so as to
confirm these results. Indeed, the dose levels of dietary isoflavones require a better definition, and the
measurements of isoflavone consumption should be provided in quantifiable terms.
With regard to the mechanisms by which isoflavones act to reduce cancer risk, it has been
suggested that the effects are due to the similarity of the isoflavone molecule to estradiol. This chemical
feature confers estrogenic or antiestrogenic effects to isoflavones, depending on the cell type and the
binding to α- or β-estrogen receptors. In this regard, it has been reported that isoflavones have a
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higher affinity to the β-estrogen receptor [7], which, contrary to the α-estrogen receptor, inhibits cell
proliferation and stimulates apoptosis [84]. Furthermore, isoflavones are able to inhibit aromatase
activity, the enzyme that converts androgen to estrogen. It is also important to mention that isoflavones
could act as potential anticancer compounds due to their antioxidant role in malignant cell proliferation
and differentiation (Figure 5).
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4.4. Menopausal Symptoms
Menopause is characterized by a decrease in estrogen levels and is often accompanied by a range of
symptoms. Among these, vasomotor symptoms comprising hot flushes and night sweats are the most
common and bothersome, which, in turn, have a negative impact on women’s quality of life. Hormone
replacement therapy has been proven to be effective in reducing vasomotor symptoms, although
isoflavones have gained popularity as an alternative treatment to hormone replacement therapy to
relieve menopausal symptoms. This is mainly due to their potential adverse effects, which range from
increased coronary heart disease to stroke and cancer [53,85]. Concerning this issue, six meta-analyses
and two systematic reviews are included in the present review (Table 5).
The six meta-analyses show a slight improvement in the frequency and intensity of hot flushes.
In the meta-analysis reported by Chen et al. (2015), the authors examined the efficacy of phytoestrogens
in reducing hot flushes [86]. The meta-analysis included 15 studies in which the number of participants
ranged from 30 to 252. The mean age of women ranged from 49 to 58.3 and 48 to 60.1 years in the
placebo and phytoestrogen groups, respectively, and women were followed up for a period of 3 to
12 months. Isoflavones were the phytoestrogens used in most of the studies; therefore, the meta-analysis
only included outcomes regarding isoflavones, while outcomes with other phytoestrogens were not
included. Ten studies reported a significant reduction in hot flush frequency in the phytoestrogen group
when compared with the placebo group. Moreover, five studies reported side-effect data, and after the
analysis, no significant differences were observed between the two groups.
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Table 5. Effects of isoflavones in menopausal symptoms.
Authors Number of StudiesIncluded
Type of Studies
Included
Number of Participants and
Gender/Age/Characteristics Compound and Doses Observed Effects
Meta-analysis




49–58.3 years (placebo group)
48–60.1 years (phytoestrogen group)
Isoflavones 5–100 mg/day
Intervention period: 3–12 months
Reduction of hot flush
frequency (vs. placebo)
Li et al., 2015 [87] 16 RCT 24–236 women/report (median 90)40–65 years
Soy isoflavones 30–200 mg/day
Intervention period: 4 weeks–2 years
(median 12 weeks)
Slight and slow attenuation of
hot flushes (vs. estradiol)




Soy isoflavones: 30–200 mg/day
Intervention period: 2–96 weeks
(average 12 weeks)
Slight and slow attenuation of
hot flushes
(vs. non-hormonal drugs)




Soy isoflavones: 33–200 mg/day and 6 g
soy extract/day
Equol: 10 mg/day
Intervention period: not available
Equol or isoflavone in
equol-producers more effective
than placebo




Isoflavones and black cohosh
(Doses not available)
Reduction of VSM




Franco et al., 2016 [90] 17 RCT 30–252 women/trial40–69 years
Dietary soy isoflavones: 42–90 mg/day
Supplements and extracts of soy
isoflavones: 10–100 mg/day
Red clover: 40–160 mg/day
Intervention period: 12–48 weeks
Reduction of hot flush
frequency by means of dietary
isoflavones and supplements)
Reduction of night sweat
frequency by red clover
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Table 5. Cont.
Authors Number of StudiesIncluded
Type of Studies
Included
Number of Participants and
Gender/Age/Characteristics Compound and Doses Observed Effects
Systematic reviews









Soy (soy nut, soy protein, soy extracts)
Natural isoflavones
Synthetic isoflavones
Beneficial effects of isoflavones
(vs. placebo)
Synthetic or combination of
isoflavones more effective than
natural soy
HRT more effective than soy or
its extracts
Isoflavone in equol-producers
or equol supplementation more
effective than placebo.
Perna et al., 2016 [52] 7 RCT 40–403 menopausal andpostmenopausal women
Isoflavones 50–120 mg/day
Intervention period: 8 weeks–2 years
Reduction of hot
flush frequency
HRT: hormone replacement therapy, RCT: randomized controlled trial, VSM: vasomotor symptoms.
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Similarly, Li et al. (2015) concluded that soy isoflavones have both a slight and slow effect in
attenuating menopausal hot flushes [87]. A total of 16 studies were included in their meta-analysis
with a range of 24 to 236 subjects. Study duration ranged from four weeks to two years, with a median
of 12 weeks. The dose of isoflavones ranged from 30 to 200 mg/day. Despite the positive effect of
isoflavones, the authors emphasized that the effects took a long time to appear. Estradiol, which has
proven efficacy on hot flushes, needs 3.09 weeks to achieve half of its peak activity, while isoflavones
require 13.4 weeks, suggesting that 12 weeks of treatment is not enough for soy isoflavones to exert
a beneficial effect. The same results were reported in another meta-analysis published by the same
authors a year later (Li et al., 2016), when they compared the efficacy of several non-hormonal drugs
on hot flushes, including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine
reuptake inhibitors (SNRIs), gabapentin, clonidine and soy isoflavones [88]. Thirty-nine studies were
included with a sample size of 200 women per trial, in which the intervention period ranged from two
to 96 weeks (median 12 weeks). As in the previous study, the onset of soy isoflavones was very slow in
comparison with other non-hormonal treatments. Specifically, the time to achieve half of the efficacy
was 11.6 weeks for soy isoflavones, while for the rest of the compounds, the onset time was near
0 weeks. They also explained that the differences between isoflavones and the rest of the drugs might
be because the latter act by modulating central neurotransmitters and, as a consequence, by regulating
the central thermoregulatory centers in the hypothalamus. In contrast, it seems that isoflavones do not
act on central neurotransmitters directly. This difference could explain the slow effect of isoflavones in
alleviating hot flushes.
Daily et al. (2019) studied whether equol supplementation could benefit equol nonproducer
subjects in lowering the incidence and severity of hot flushes [85]. Equol is produced from the
isoflavone daidzein by intestinal bacteria, mainly in the large intestine. Their meta-analysis included
five studies with a total of 728 menopausal women between 50.5 and 58.5 years old and concluded that
women who are not able to produce equol could benefit from equol supplementation. On the contrary,
women who were already equol producers did not obtain any additional benefit from supplements of
equol or isoflavones.
Another meta-analysis explored the effects of several pharmacological and non-pharmacological
treatments in the relief of vasomotor symptoms, taking into account not only hot flushes but also night
sweats [89]. Non-pharmacological treatments included isoflavones, which appeared to be better than
placebo in the relief of vasomotor symptoms, although not significantly better than the treatment with
estradiol and progesterone. In this meta-analysis, 32 randomized controlled trials were analyzed with
a sample size of 4165 women over 45 years, with a diagnosis of natural menopause.
Franco et al. (2016) also studied whether there was an association between different types of
interventions and the reduction in hot flushes and night sweats [90]. They performed a separated
meta-analysis for each of the interventions, including dietary soy isoflavones (including four studies),
supplements and extracts of soy isoflavones (including six studies) and red clover isoflavones
(including seven studies). They found that the use of dietary isoflavones or supplements and extracts
was associated with an improvement in hot flushes, but not with a reduction in the frequency of night
sweats. In contrast, red clover was not associated with changes in the hot flush frequency. Only one
study examined the effects of red clover on night sweats, and a significant association was found,
which showed a decreased frequency in night sweats.
The two systematic reviews conclude that isoflavones have an important role in reducing hot
flushes [52,53], although some observations need to be pointed out. Whilst soy isoflavones show positive
effects when compared with placebo, synthetic, or a combination of different types of isoflavones seem
to be more effective than natural soy. When a group receiving hormone replacement therapy was
included in the study, significant differences between the effects of hormone replacement therapy and
soy were found, being the effect of the former superior to that of isoflavones. Two of the studies also
revealed that women who were able to produce equol or who had received equol supplementation
could have had a greater benefit from isoflavones [53]. Perna et al. (2016) reviewed seven studies and
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concluded that the evidence supports the fact that isoflavones, at a dose of 50–20 mg/day, decrease the
frequency of hot flushes [52].
In general, evidence regarding the use of isoflavones on vasomotor symptoms suggests that
they could be useful in reducing hot flushes. However, there is still a great heterogeneity among
studies, which makes the current data inconclusive. Regarding the mechanisms by which isoflavones
act to alleviate vasomotor symptoms, is has been proposed that they bind to estrogen receptors and
activate endothelial nitric oxide synthase (eNOS) transcription, leading to eNOS synthesis and nitric
oxide production, the main mediator of vasodilatation, which allows cutaneous heat dissipation [91]
(Figure 6).
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5. Side Effects and Safety
Potential health adverse effects in the intake of isoflavones have been postulated due to their
estrogenic activity, especially in relation to breast cancer. However, it is important to mention that this
connection has been established based on pre-clinical studies, whereas data derived from clinical trials
have not demonstrated such association [92]. In fact, in 2015, in relation to the possible adverse effects on
the mammary gland, uterus and thyroid, the European Food Safety Agency (EFSA) offered a scientific
opinion with regards to the assessment of potential increased risk in peri- and postmenopausal women
who took food supplements that contained isolated isoflavones. After an extensive bibliographical
review, the expert panel concluded that the results of observational studies do not support the
hypothesis of an increased risk of breast cancer after isoflavone-rich food supplement intake [93].
Moreover, an increase in thyroid hormone levels after isoflavone intake by food supplements has
not been observed, and no side effects were confirmed with regard to the endometrial thickness or
histopathological changes in the uterus. Thus, the EFSA scientific committee’s opinion agreed that
isoflavone intake was safe, at least in the doses that the analyzed studies have used. In any case,
it is important to bear in mind that a great number of expert scientists and doctors think that breast
cancer survivors should not increase their isoflavone intake [94], although others consider that their
consumption is safe and beneficial [95]. In general terms, caution should be exercised with the use of
high doses of isoflavones in women with a family history of breast cancer [49].
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Finally, it is important to mention that despite the fact that potential isoflavone adverse effects have
been widely studied, little is known about the side effect of the bacterial metabolite equol. As it has
been stated in the Bioavailability section, microbiota composition in humans makes equol production
very variable, which yields high interindividual differences. Reproductive and developmental toxicity
studies have stated that 1 g and 2 g of equol per day is safe [96], although further studies are
required [92].
6. Concluding Remarks
In view of the results gathered in the present review, we can conclude that there is scientific
evidence that reveals the beneficial effect of isoflavones on bone health and thus in the prevention and
treatment of osteoporosis in postmenopausal women. Nevertheless, the results do not seem entirely
conclusive, as there are discrepancies among the studies included in the systematic reviews and in the
meta-analyses, probably related to their experimental designs. For this reason, the results should be
interpreted with caution, and more randomized clinical trials are imperative. By contrast, it seems
that soy isoflavones do not lead to a meaningful protective effect on cardiovascular risk. Regarding
cancer, scientific evidence suggests that isoflavones could be useful in reducing the risk of suffering
from some types of cancer, such as breast and endometrial cancer, although further studies are needed
to confirm these results. In the end, isoflavones could be useful in reducing hot flushes associated with
menopause. However, a limitation in this field is that there is still a great heterogeneity among studies.
Altogether, these results show that further studies are needed in order to find stronger conclusions.
Considering the isoflavone chemical structure, potential health adverse effects of these compounds
related to their estrogenic activity have been postulated, despite the scientific opinion offered by EFSA
indicating that isoflavone intake was safe.
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